Joined June 2010
- Tweets 11,761
- Following 103
- Followers 524
- Likes 806
275 Photos and videos
FWCStocks retweeted
Jun 10
$TECX •APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)
•APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched population of CpcPH with a pulmonary vascular resistance (PVR) >3 WU at baseline
•TX45 APEX Phase 2 topline results expected in early Q1 2027
Jun 10
$TECX Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients investors.tectonictx.com/new…
1
7
3,475
FWCStocks retweeted
Jun 10
$TECX Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients globenewswire.com/news-relea…
1
5
985
Jun 8
$VERA PDUFA decision less than 1-month away for the IGaN kidney drug Atacicept. 90% probability of approval with full workforce already in place. Looking for 100% upside on approval.
1
4
609
Jun 5
Out of 50 stocks on my watch list, only KURA and VRTX are green...barely. Rough day for the XBI. But some of my buy targets hit so I continue to take advantage of the dips.
89
Jun 5
$SABS data readout today. “Clinical Safety, Pharmacokinetics, Immunogenicity, and Pharmacodynamics following Repeat Dosing of SAB-142, a Fully Human Multi-Specific Antithymocyte Globulin for New-Onset Type 1 Diabetes”.
1
257
Jun 5
The article is correct. $KYTX is set to become the first FDA approval here. Kyverna is also way oversold and a screaming buy.
Jun 4
In the race to turn CAR-T cell therapies against autoimmune diseases, Cabaletta Bio has always been blazing its own trail. fiercebiotech.com/biotech/wh…
1
583
Jun 3
$VERA is on sale.
RECENT PRICE TARGETS:
Wells Fargo: $90
HC Wainwright: $110
Cantor: $100
Goldman: $90
Wolfe: $88
LifeSci: $90
BofA: $65
JPM: $86
Evercore: $91
Jeffries: $45
1
3
5
842
FWCStocks retweeted
We’re excited to announce we have achieved alignment with the FDA on an earlier ORIGIN Phase 3 analysis to support potential full approval for our investigational therapy in IgA nephropathy. Read the press release: ir.veratx.com/news-releases/…
1
144
Jun 3
$KYTX Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis.
ir.kyvernatx.com/news-releas…
2
347
Jun 2
Raymond James: Rare unique buying opportunity for $VERA after today's news and the recent selloff.
2
3
582